Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients

European Journal of Clinical Investigation

Volumn 37, Issue 6, 2007, Pages 454-462

  Guazzi, M ^a   Tumminello, G ^a   Reina, G ^a   Vicenzi, M ^a   Guazzi, M D ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Endothelium; Exercise; Oxygen kinetics; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; PLACEBO;

ADULT; ARTICLE; BRACHIAL ARTERY; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; ENDOTHELIUM; EXERCISE; FEMALE; GAS EXCHANGE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; KINETICS; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WORKLOAD;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXYGEN CONSUMPTION; PYRROLES;

EID: 34249687024     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01805.x     Document Type: Article

References (35)

1. Vaugham CJ, Gotto AM. Update on statin: 2003. Circulation 2004 110: 886 92.
2. ACC/ AHA, Practice Guidelines. Management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 2004 44: 671 19.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344: 1383 9.
4. Pedersen TR, Olson AG, Faergeman O, Kiekshus J, Wedel H, Berg K et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998 97: 1453 60.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 335: 1001 9.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 333: 1301 7.
7. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J Clin Epidemiol 1992 45: 849 60.
8. Halcox JPJ, Deanfield JE. Beyond the laboratory. Clinical Implications for statin pleiotropy. Circulation 2004: 109: II42 8.
9. Davidson MH. Clinical significance of statin pleiotropic effects. Hypothesis versus evidence. Circulation 2004 109 (21 Suppl. 1 II42 8.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002 360: 7 22.
11. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 261: 1149 58.
12. Lewis BS, Emmott SN, Smyllie J, MacNeil AB, Lubsen J. Left ventricular systolic and diastolic function, and exercise capacity six to eight weeks after acute myocardial infarction. The DEFIANT Study Group. Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy. Am J Cardiol 1993 72: 149 53.
13. Adamopoulos S, Kemp KJ, Thompson CH, Arnolda L, Brunotte F, Stratton JR et al. The time-course of hemodynamic, autonomic and skeletal muscle metabolic abnormalities following first extensive myocardial infarction in man. J Mol Cell Cardiol 1999 31:1913 26.
14. Koike A, Hiroe M, Adachi H, Yajima T, Yamauchi Y, Nogami A et al. Oxygen uptake kinetics are determined by cardiac function at onset of exercise in patients with prior myocardial infarction. Circulation 1994 90:2324 32.
15. Jarvisalo MJ, Toikka JO, Vasankari T, Mikkola J, Viikari JS, Hartiala JJ et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999 147:237 42.
16. Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H. Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects. Cardiovasc Res 2006 72:438 46.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18:499 502.
18. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL et al. ACC; AHA; ASE. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003 16:1091 110.
19. Corretti MC, Anderson TJ, Gearard-Herman M, Herrington D, Vallace P, Vita J et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002 39:257 65.
20. Guazzi M, Belletti S, Bianco E, Lenatti L, Guazzi MD. Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion. Am J Physiol 2006 291:H921 8.
21. Liem AH, van Boven AJ, Veeger NJGM, Withagen AJ, Robles de Medina RM, Tijenssen JGP et al. for the Fluvastatin On Risk Diminishment after Acute myocardial infarction (FLORIDA) Study Group. Effect of fluvastatin on ischemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002 23:1931 7.
22. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci W. Statins inhibit β-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a RAC1-dependent mechanism. Circulation 2004 110:412 8.
23. Tanaka K, Honda M, Takabatake T. Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 2004 31:360 4.
24. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003 108:839 43.
25. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiu AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2002 157:463 9.
26. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003 107:2493 8.
27. Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Cir Res 2004 95:217 23.
28. Wolfrum S, Jensen KS, Liao KJ. Endothelium-dependent effects of statins. Artherioscler Thromb Vasc Biol 2003 23:729 36.
29. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003 108:426 31.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999 100:230 5.
31. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jalal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002 106:1439 41.
32. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Bediwala MV et al. A self fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002 106:913 9.
33. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004 12:2339 48.
34. Wilkerson DP, Campbell IT, Jones AM. Influence of nitric oxide synthase inhibition on pulmonary O2 uptake kinetics during supra-maximal exercise in humans. J Physiol 2004 561:623 35.
35. McDonough P, Behnke BJ, Musch TI, Poole DC. Recovery of microvascular PO2 during the exercise off-transient in muscles of different fiber type. J Appl Physiol 2004 96:1039 44.